Characterization of CTL Recognized Epitopes on Human Breast Tumors
Abstract
The overall objective of this proposal is to develop novel therapeutic approaches to breast cancer by understanding the molecular and cellular basis of tumor antigen (Ag) recognition by cytotoxic T lymphocytes (CTL). Characterization of HLA-A2 bound peptides by comparison of CTL activity and signal intensity of peptides by mass-spectrometry has lead to identification of a novel tumor Ag, defined by a peptide epitope from the amino-enhancer of split (AES) protein. This protein is part of the "Notch" complex involved in regulation of cell fate during development. This Ag is recognized both by breast and ovarian tumor reactive cell lines. Studies on HER-2 tumor Ag identification and epitope optimization have also led to design of a novel clinical trial with the peptide E75: HER-2 (369 - 377) for patients with breast and ovarian cancer. To address the significance of these epitopes we are currently exploring the ability of the corresponding peptides to induce tumor specific immunity.
Document Details
- Document Type
- Technical Report
- Publication Date
- Sep 01, 1996
- Accession Number
- ADB218882
Entities
People
- Constantin G. Ioannides
Organizations
- University of Texas at Austin